The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,810.00
Bid: 1,811.00
Ask: 1,811.50
Change: 0.00 (0.00%)
Spread: 0.50 (0.028%)
Open: 1,805.00
High: 1,812.50
Low: 1,797.00
Prev. Close: 1,810.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Brexit spells upheaval for EU and UK drug regulation

Fri, 24th Jun 2016 11:41

* European Medicines Agency may have to move from London

* Duplicate regulatory system could cause confusion

* Currency moves to influence company earnings

By Ben Hirschler

LONDON, June 24 (Reuters) - Britain's vote to leave theEuropean Union spells regulatory uncertainty for drug companies,with the London-based European Medicines Agency (EMA), whichapproves treatments for all EU countries, expected to have torelocate.

The association of Germany's pharmaceuticals industry saidon Friday that Europe's equivalent of the U.S. Food and DrugAdministration would need to move to a city within the EU,bringing administrative headaches for companies.

Britain's biggest drugmaker, GlaxoSmithKline, saidthe exit vote "creates uncertainty and potentially complexityfor us in the future", though the impact on its global businesswould be small, while the UK pharma trade association warned ofchallenges to future investment, research and jobs.

Industry executives fear upheaval at the EMA could snarl theEU's drug approval process and Britain may have to develop itsown domestic regulatory system, leading to further confusion.

Although Britain could continue to take part in the EMAsystem if it remains in the European Economic Area, like Norway,many of those supporting its exit from the EU oppose thatoption.

As a result, British patients could move to the back of thequeue for new medicines as companies prioritise the larger EUmarket, and some medicines could be left in regulatory limbo.

The EMA, with a full-time staff of more than 600, is thelargest EU body in Britain and has overseen pan-European drugapprovals since 1995 from its headquarters tucked away amongglobal banks in London's Canary Wharf.

An EMA spokeswoman said it was premature to comment on itsfuture. "It is too early to foresee the implications of thisdecision and at this stage we are waiting for further guidancefrom the European Commission," she said.

Drug companies and healthcare officials in Sweden, Denmark,Italy and Germany have all expressed interest in hosting the EMAinstead of London, since firms in these countries are keen to belocated close to the region's key regulator.

CURRENCY IMPACT

The impact on profits of Britain's EU exit will be limitedfor many global drug manufacturers as the United States is byfar the largest market for prescription medicines and Asia isalso of growing importance.

GSK said it did not anticipate a material hit to itsbusiness -- and in the short term analysts expect it to enjoy anearnings boost from a weaker pound as overseas revenues aretranslated into sterling.

AstraZeneca, which reports in dollars, and Swissrival Roche won't enjoy such a currency lift but bothsaid it was vital that Britain continued to support the lifesciences industry in the wake of the referendum.

The pharmaceuticals industry employs more than 70,000 peoplein the UK and accounts for 25 percent of all business researchand development spending in the country.

Many scientists are concerned that funding for academicresearch, which has been well supported by the EU in recentdecades, will now be jeopardised, along with importantUK-European research collaborations.

"Now that the direction has been set to leave the EU, it iscrucial that the government develops clear plans to safeguardthe future of science and research in the UK," said RobertLechler, president of the Academy of Medical Sciences. (Additional reporting by Ludwig Burger in Frankfurt; Editing byKeith Weir)

More News
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more
30 Apr 2024 12:22

Sensodyne-maker Haleon to shut UK plant, 435 jobs to go

April 30 (Reuters) - Haleon, the world's largest standalone consumer healthcare firm, will shut its UK production site which makes Sensodyne toothpastes by 2026, leading to 435 job losses, a spokesperson said on Tuesday.

Read more
25 Apr 2024 15:53

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines.

Read more
24 Apr 2024 14:19

UK earnings, trading statements calendar - next 7 days

Thursday 25 April 
Aquila European Renewables PLCFull Year Results
Argo Blockchain PLCFull Year Results
AstraZeneca PLCQ1 Results
Barclays PLCQ1 Results
Checkit PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Destiny Pharma PLCFull Year Results
Dillistone Group PLCFull Year Results
Focusrite PLCHalf Year Results
Gem Diamonds LtdTrading Statement
Hikma Pharmaceuticals PLCTrading Statement
Hummingbird Resources PLCTrading Statement
Ibstock PLCTrading Statement
Inchcape PLCTrading Statement
J Sainsbury PLCFull Year Results
London Stock Exchange Group PLCQ1 Results
Persimmon PLCTrading Statement
Pinewood Technologies Group PLCFull Year Results
PPHE Hotel Group LtdTrading Statement
PureTech Health PLCFull Year Results
Relx PLCTrading Statement
Renewi PLCTrading Statement
Schroders PLCQ1 Results
Skillcast Group PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
Unilever PLCQ1 Results
WAG Payment Solutions PLCTrading Statement
Weir Group PLCTrading Statement
WH Smith PLCHalf Year Results
WPP PLCTrading Statement
Zinc Media Group PLCFull Year Results
Friday 26 April 
Facilities by ADF PLCFull Year Results
Kingspan Group PLCTrading Statement
Loungers PLCTrading Statement
NatWest Group PLC Q1 Results
Pearson PLCTrading Statement
Record PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Taylor Maritime Investments LtdTrading Statement
Monday 29 April 
Beazley PLCTrading Statement
Biome Technologies PLCFull Year Results
Christie Group PLCFull Year Results
Gresham House Energy Storage Fund PLCFull Year Results
Gresham Technologies PLCFull Year Results
Jadestone Energy PLCFull Year Results
Oxford BioMedica PLCFull Year Results
SpaceandPeople PLCFull Year Results
Tuesday 30 April 
Avacta Group PLCFull Year Results
Card Factory PLCFull Year Results
Capital & Regional PLCFull Year Results
Close Brothers Group PLCTrading Statement
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCHalf Year Results
Fadel Partners IncFull Year Results
Glencore PLCTrading Statement
Hargreaves Lansdown PLC Trading Statement
Howden Joinery PLCTrading Statement
HSBC Holdings PLCQ1 Results
Kelso Group PLCFull Year Results
Northcoders Group PLCFull Year Results
Phoenix Spree Deutschland LtdFull Year Results
RBG Holdings PLCFull Year Results
Rotork PLCTrading Statement
Safestore Holdings PLCHalf Year Results
Shield Therapeutics PLCFull Year Results
St James's Place PLCTrading Statement
Strip Tinning Holdings PLCFull Year Results
Whitbread PLCFull Year Results
Wednesday 1 May 
Computacenter PLCTrading Statement
GSK PLCQ1 Results
Haleon PLCTrading Statement
HSS Hire Group PLCFull Year Results
Intelligent Ultrasound Group PLCFull Year Results
Maintel Holdings PLCFull Year Results
Next PLCTrading Statement
Smith & Nephew PLCTrading Statement
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
24 Apr 2024 09:21

GSK's endometrial cancer drug receives FDA approval

(Sharecast News) - Drugmaker GSK said on Wednesday that the US Food and Drug Administration has accepted a supplemental Biologics License Application for Jemperli, its drug aimed at treating endometrial cancer.

Read more
24 Apr 2024 09:14

GSK's Jemperli with chemotherapy accepted for priority review by FDA

(Alliance News) - GSK PLC on Wednesday said that the US Food & Drug Administration has accepted a supplemental biologics licence application for Jemperli, when used in combination with chemotherapy.

Read more
17 Apr 2024 08:46

TOP NEWS: GSK hails data on Shingles vaccine and gonorrhoea treatment

(Alliance News) - GSK PLC on Wednesday reported new test data for its shingles vaccine and for a potential new oral treatment for a form of gonorrhoea.

Read more
17 Apr 2024 07:11

GSK posts promising results from gonorrhoea treatment trial

(Sharecast News) - GSK unveiled encouraging outcomes from a pivotal phase three trial on Wednesday, on the potential of gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea (GC), amid escalating resistance to current therapies.

Read more
16 Apr 2024 09:17

GSK meningococcal vaccine accepted by US FDA for review

(Sharecast News) - GSK announced on Tuesday that its five-in-one meningococcal ABCWY (MenABCWY) vaccine candidate had been accepted for regulatory review by the US Food and Drug Administration (FDA).

Read more
16 Apr 2024 08:59

GSK's latest meningitis vaccine accepted for review by US regulator

(Alliance News) - GSK PLC on Tuesday said it has made progress in the development of its newest candidate, which combines the strengths of two other vaccines in its portfolio into one bacteria-fighting inoculation.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.